Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jiuzhitang Co., Ltd. (000989.SZ)
Beijing, CN
Jiuzhitang Co., Ltd. is a Chinese pharmaceutical company specializing in the development and distribution of traditional Chinese, chemical, biological, and health-related medicinal products. Its product portfolio addresses a wide array of health concerns. For instance, cardiovascular and cerebrovascular conditions are treated with offerings like shuxuetong injections, Angong Niuhuang Wan, Danxi granules, and Gastrodia Uncaria. Gynecological issues are targeted by Guizhi Fuling pills, Buxue Shengru granules, and other hemostasis and analgesic preparations. Respiratory ailments can be managed with Schicon, while digestive disorders benefit from products such as Jiaqi Ganzian granules, Jianwei Yuyang tablets, Jienchang Ning, and Chidan yellowing products. Furthermore, the company supplies a comprehensive range of over-the-counter (OTC) medications. These non-prescription drugs support areas including qi and blood nourishment, cardiovascular and cerebrovascular health, urinary system function, pediatric care, women's health, musculoskeletal wellness, respiratory relief, dermatological conditions, nervous system support, ENT treatments, digestive aid, and even tumor-related concerns. Established in Beijing, China, in 1999, Jiuzhitang Co., Ltd. maintains its headquarters there.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.02% | -3.81% | -17.15% | -10.43% | -14.60% | -7.56% | -5.28% | -39.73% | -16.29% | -60.61% | -25.21% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-6.9% Q1'26: +20.8% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+4.0% Q1'26: +35.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+16.5% ★ Q1'26: +9.6% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+11.2% Q1'26: +24.7% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+6.3% Q1'26: +24.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.5% ★ Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.37× ★ Q1'26: 0.09× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4.01B
est.
|
3.78B
est: 3.09B (+22.5%)
|
3.03B
est: 3.50B (-13.3%)
|
2.96B
est: 3.50B (-15.4%)
|
2.37B
est: 4.21B (-43.7%)
|
2.21B
est: 2.27B (-3.0%)
|
2.74B
2.74B – 2.74B
+20.7% YoY
|
3.19B
3.19B – 3.19B
+16.3% YoY
|
3.58B
3.58B – 3.58B
+12.1% YoY
|
| EBITDA |
519.11M
est.
|
479.41M
est: 399.61M (+20.0%)
|
579.05M
est: 452.51M (+28.0%)
|
473.88M
est: 452.51M (+4.7%)
|
366.83M
est: 810.28M (-54.7%)
|
373.59M
est: 437.36M (-14.6%)
|
527.85M
527.85M – 527.85M
+20.7% YoY
|
614.10M
614.10M – 614.10M
+16.3% YoY
|
688.54M
688.54M – 688.54M
+12.1% YoY
|
| EBIT |
369.11M
est.
|
365.98M
est: 284.14M (+28.8%)
|
459.66M
est: 321.75M (+42.9%)
|
354.75M
est: 321.75M (+10.3%)
|
255.46M
est: 495.29M (-48.4%)
|
247.21M
est: 267.33M (-7.5%)
|
322.65M
322.65M – 322.65M
+20.7% YoY
|
375.37M
375.37M – 375.37M
+16.3% YoY
|
420.87M
420.87M – 420.87M
+12.1% YoY
|
| Net Income |
263.56M
est.
|
270.70M
est: 331.57M (-18.4%)
|
357.99M
est: 433.59M (-17.4%)
|
297.41M
est: 433.59M (-31.4%)
|
216.20M
est: 541.62M (-60.1%)
|
222.60M
est: 203.11M (+9.6%)
|
300.43M
300.43M – 300.43M
+47.9% YoY
|
359.67M
359.67M – 359.67M
+19.7% YoY
|
401.98M
401.98M – 401.98M
+11.8% YoY
|
| SGA |
1.76B
est.
|
1.67B
est: 1.36B (+23.2%)
|
1.35B
est: 1.54B (-12.1%)
|
1.31B
est: 1.54B (-14.7%)
|
1.04B
est: 1.82B (-42.8%)
|
858.34M
est: 981.77M (-12.6%)
|
1.18B
1.18B – 1.18B
+20.7% YoY
|
1.38B
1.38B – 1.38B
+16.3% YoY
|
1.55B
1.55B – 1.55B
+12.1% YoY
|
| EPS |
0.31
est.
|
0.32
est: 0.39 (-17.9%)
|
0.42
est: 0.51 (-17.6%)
|
0.35
est: 0.51 (-31.4%)
|
0.25
est: 0.64 (-60.9%)
|
0.26
est: 0.24 (+8.3%)
|
0.36
0.36 – 0.36
+47.9% YoY
|
0.43
0.43 – 0.43
+19.7% YoY
|
0.48
0.48 – 0.48
+11.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-25 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | VanEck - China New Economy ETF CNEW.AX | 0.93% | 660.0K | 0.95% |
| 2 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 179.0K | 0.39% |
| 3 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 33.6K | 0.46% |
| 4 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 107.5K | 0.29% |
| 5 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 91.1K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chenxiao Han | Secretary | — | male |
| Chunfeng Liu | Deputy General Manager | — | female |
| Li Zhen Guo | Vice Chairman & General Manager | — | male |
| Liangbin Zhang | Deputy General Manager | — | male |
| Lubao Zhou | Chief Financial Officer & Head of Accounting | — | male |
| Xu Xiang Ping | Deputy General Manager | — | male |
| Yansong Gao | Deputy General Manager | — | male |
| Yongsheng Wu | Deputy General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 000989.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
